Liven Pharma Limited (PSX:LIVEN)
Pakistan
· Delayed Price · Currency is PKR 52.99
+1.88 (3.68%)
At close: Dec 5, 2025
Liven Pharma Income Statement
Financials in millions PKR. Fiscal year is July - June.
Millions PKR. Fiscal year is Jul - Jun.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2020 - 2016 |
| Revenue | 127.27 | 245.09 | - | - | - | Upgrade
|
| Revenue Growth (YoY) | -48.07% | - | - | - | - | Upgrade
|
| Cost of Revenue | 111.45 | 182.96 | - | - | - | Upgrade
|
| Gross Profit | 15.82 | 62.14 | - | - | - | Upgrade
|
| Selling, General & Admin | 389.03 | 19.14 | 2.12 | 2.95 | 2.1 | Upgrade
|
| Other Operating Expenses | 88.84 | 1.23 | - | - | - | Upgrade
|
| Operating Expenses | 507.53 | 20.37 | 15.22 | 17.51 | 18.19 | Upgrade
|
| Operating Income | -491.71 | 41.77 | -15.22 | -17.51 | -18.19 | Upgrade
|
| Interest Expense | -0.73 | -0.02 | - | - | - | Upgrade
|
| Interest & Investment Income | 0.31 | - | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | -0.06 | -0 | -0 | -0 | -0 | Upgrade
|
| EBT Excluding Unusual Items | -492.19 | 41.74 | -15.23 | -17.51 | -18.19 | Upgrade
|
| Pretax Income | -492.19 | 41.74 | -15.23 | -17.51 | -18.19 | Upgrade
|
| Income Tax Expense | 92.27 | - | -2.9 | -3.22 | -3.55 | Upgrade
|
| Net Income | -584.46 | 41.74 | -12.33 | -14.29 | -14.63 | Upgrade
|
| Net Income to Common | -584.46 | 41.74 | -12.33 | -14.29 | -14.63 | Upgrade
|
| Shares Outstanding (Basic) | 70 | 0 | 12 | 12 | 12 | Upgrade
|
| Shares Outstanding (Diluted) | 70 | 0 | 12 | 12 | 12 | Upgrade
|
| Shares Change (YoY) | 174375.69% | -99.67% | - | - | - | Upgrade
|
| EPS (Basic) | -8.37 | 1043.60 | -1.02 | -1.18 | -1.21 | Upgrade
|
| EPS (Diluted) | -8.37 | 1043.60 | -1.02 | -1.18 | -1.21 | Upgrade
|
| Free Cash Flow | -24.56 | 13.8 | -2.27 | -2.26 | -6.79 | Upgrade
|
| Free Cash Flow Per Share | -0.35 | 345.08 | -0.19 | -0.19 | -0.56 | Upgrade
|
| Gross Margin | 12.43% | 25.35% | - | - | - | Upgrade
|
| Operating Margin | -386.34% | 17.04% | - | - | - | Upgrade
|
| Profit Margin | -459.22% | 17.03% | - | - | - | Upgrade
|
| Free Cash Flow Margin | -19.30% | 5.63% | - | - | - | Upgrade
|
| EBITDA | -465.93 | 64.93 | -2.12 | -2.95 | -2.1 | Upgrade
|
| EBITDA Margin | - | 26.49% | - | - | - | Upgrade
|
| D&A For EBITDA | 25.78 | 23.16 | 13.1 | 14.56 | 16.08 | Upgrade
|
| EBIT | -491.71 | 41.77 | -15.22 | -17.51 | -18.19 | Upgrade
|
| EBIT Margin | - | 17.04% | - | - | - | Upgrade
|
| Advertising Expenses | 3.26 | 0.12 | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.